Literature DB >> 12111840

Stem cell repair of central nervous system injury.

Qilin Cao1, Richard L Benton, Scott R Whittemore.   

Abstract

Neural stem cells (NSCs) have great potential as a therapeutic tool for the repair of a number of CNS disorders. NSCs can either be isolated from embryonic and adult brain tissue or be induced from both mouse and human ES cells. These cells proliferate in vitro through many passages without losing their multipotentiality. Following engraftment into the adult CNS, NSCs differentiate mainly into glia, except in neurogenic areas. After engraftment into the injured and diseased CNS, their differentiation is further retarded. In vitro manipulation of NSC fate prior to transplantation and/or modification of the host environment may be necessary to control the terminal lineage of the transplanted cells to obtain functionally significant numbers of neurons. NSCs and a few types of glial precursors have shown the capability to differentiate into oligodendrocytes and to remyeliate the demyelinated axons in the CNS, but the functional extent of remyelination achieved by these transplants is limited. Manipulation of endogenous neural precursors may be an alternative therapy or a complimentary therapy to stem cell transplantation for neurodegenerative disease and CNS injury. However, this at present is challenging and so far has been unsuccessful. Understanding mechanisms of NSC differentiation in the context of the injured CNS will be critical to achieving these therapeutic strategies. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12111840     DOI: 10.1002/jnr.10240

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  54 in total

Review 1.  Taking a bite out of spinal cord injury: do dental stem cells have the teeth for it?

Authors:  John Bianco; Pauline De Berdt; Ronald Deumens; Anne des Rieux
Journal:  Cell Mol Life Sci       Date:  2016-01-14       Impact factor: 9.261

2.  Expression of hyaluronan and the hyaluronan-binding proteoglycans neurocan, aggrecan, and versican by neural stem cells and neural cells derived from embryonic stem cells.

Authors:  Mary Abaskharoun; Marie Bellemare; Elizabeth Lau; Richard U Margolis
Journal:  Brain Res       Date:  2010-02-20       Impact factor: 3.252

Review 3.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

Review 4.  Genetic manipulation of neural stem cells for transplantation into the injured spinal cord.

Authors:  Bor Luen Tang; Choon Bing Low
Journal:  Cell Mol Neurobiol       Date:  2006-12-07       Impact factor: 5.046

5.  Differential fate of multipotent and lineage-restricted neural precursors following transplantation into the adult CNS.

Authors:  Angelo C Lepore; Steven S W Han; Carla J Tyler-Polsz; Jingli Cai; Mahendra S Rao; Itzhak Fischer
Journal:  Neuron Glia Biol       Date:  2004-05

Review 6.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 7.  Stem cell myths.

Authors:  Tim Magnus; Ying Liu; Graham C Parker; Mahendra S Rao
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-01-12       Impact factor: 6.237

Review 8.  Don't fence me in: harnessing the beneficial roles of astrocytes for spinal cord repair.

Authors:  Robin E White; Lyn B Jakeman
Journal:  Restor Neurol Neurosci       Date:  2008       Impact factor: 2.406

Review 9.  Axon regeneration and exercise-dependent plasticity after spinal cord injury.

Authors:  John D Houle; Marie-Pascale Côté
Journal:  Ann N Y Acad Sci       Date:  2013-03       Impact factor: 5.691

10.  Glypican-1, phosphacan/receptor protein-tyrosine phosphatase-ζ/β and its ligand, tenascin-C, are expressed by neural stem cells and neural cells derived from embryonic stem cells.

Authors:  Mary Abaskharoun; Marie Bellemare; Elizabeth Lau; Richard U Margolis
Journal:  ASN Neuro       Date:  2010-07-30       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.